Conversion from Extended-Dose-Release Tacrolimus to Melt-Dose Tacrolimus in High Metabolizer Patients: Is the New Formulation of LPCT the Best Option for High Metabolizer Kidney Transplanted Patients?

Main Article Content

Paolo Carta
Federica Curci
Leonardo Caroti
Larti Aida
Lorenzo Di Maria
Lino Cirami

Keywords

kidney transplantation; extended-dose-release Tacrolimus; melt-dose Tacrolimus; renal function; tremors; high metabolizer recipients

Abstract

Tacrolimus (FK506) is the most widely used anti-rejection drug in kidney transplantation, especially its extended release Tacrolimus formulation (ER-Tac, Advagraf), which is used when target blood levels can be difficult to reach in high metabolizer patients. In this retrospective monocentric study, we analyzed the effect of a switch from ER-Tac to LifeCycle Pharma Tacrolimus (LPCT, Envarsus) on the dose/level ratio of FK506 in high metabolizer patients that cannot achieve target blood levels in the first 6 months after transplantation.
We observed a statistically significant improvement in the level to dose ratio after the switch. Renal function remained stable. We also observed a reduction in the development of tremors.


Our data suggest that LPCT can be used in a safer way in high metabolizer kidney transplant recipients.

Downloads

Download data is not yet available.
Abstract 371 | PDF Downloads 51 HTML Downloads 13 XML Downloads 11

References

1. Philosophe B, Leca N, West-Thielke PM, Horwedel T, Culkin-Gemmell C, Kistler K, et al. Evaluation of flexible tacrolimus drug concentration monitoring approach in patients receiving extended-release once-daily tacrolimus tablets. J Clin Pharmacol. 2018 Jul;58(7):891–6. http://dx.doi.org/10.1002/jcph.1082
2. Tremblay S, Nigro V, Weinberg J, Woodle ES, Alloway RR. A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): An open-label, prospective, randomized, two-arm, three-period crossover study. Am J Transplant. 2017 Feb;17(2):432–42. http://dx.doi.org/10.1111/ajt.13935
3. Gaber AO, Alloway RR, Bodziak K, Kaplan B, Bunnapradist S. Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): A phase 2 trial of stable renal transplant recipients. Transplantation. 2013;96(2):191–7. http://dx.doi.org/10.1097/TP.0b013e3182962cc1
4. Bunnapradist S, Ciechanowski K, West-Thielke P, Mulgaonkar S, Rostaing L, Vasudev B, et al. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): The phase III randomized MELT trial. Am J Transplant. 2013;13(3):760–9. http://dx.doi.org/10.1111/ajt.12035
5. Bunnapradist S, Rostaing L, Alloway RR, West-Thielke P, Denny J, Mulgaonkar S, et al. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: A pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Transpl Int. 2016;29(5):603–61. http://dx.doi.org/10.1111/tri.12770
6. Trofe-Clark J, Brennan DC, West-Thielke P, Milone MC, Lim MA, Neubauer R, et al. Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate release tacrolimus versus extended release tacrolimus in African American kidney transplant recipients. Am J Kidney Dis. 2018;71(3):315–26. http://dx.doi.org/10.1053/j.ajkd.2017.07.018
7. Langone A, Steinberg SM, Gedaly R, Chan LK, Shah T, Sethi KD, et al. Switching study of kidney transplant patients with tremor to LCP-TacrO (STRATO): An open-label, multicenter, prospective phase 3b study. Clin Transplant. 2015;29(9):796–805. http://dx.doi.org/10.1111/ctr.12581